about
Thalidomide analogues as anticancer drugsEffective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide.Reductive metabolism of oxymatrine is catalyzed by microsomal CYP3A4.Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotypeRapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology.In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticityHuman cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice.The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage.
P2860
Q24670383-8EA36912-3C6B-4310-AEDE-92CD64EC2B56Q35166127-14818A57-5DA9-4387-AA8A-6E005BD57556Q36257083-A694D8D8-221A-4FF5-AA4F-DEFA5F03DEA4Q36821724-455F6533-C780-44FA-A6C5-E5036414450FQ36944006-70CF7133-D847-49A4-9AA2-90CD91AE437AQ37162141-2997F0D9-0F8F-431F-A952-47F87C2B810DQ37624853-D7274808-E552-427C-B37B-FD4FB67E730BQ38622206-9BCB329E-DD05-409A-95C1-E2268AA65A0CQ41882029-97D98740-4F28-44F1-82E7-86BBEF404C96Q41966805-76E9D4AA-683B-4FD6-A1B4-5CADFBCB2005Q42070178-7EEA6717-5198-426D-A733-AC2F66F0CB87Q42861145-1159D94B-7D62-4441-A4A8-86D3F5E252CBQ42870979-800CA055-9ADC-4128-8E1F-E7B59FAF1651Q46330701-DA2A2C1C-A703-46B2-8160-E78338BD4432
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Thalidomide metabolism by the CYP2C subfamily.
@ast
Thalidomide metabolism by the CYP2C subfamily.
@en
Thalidomide metabolism by the CYP2C subfamily.
@nl
type
label
Thalidomide metabolism by the CYP2C subfamily.
@ast
Thalidomide metabolism by the CYP2C subfamily.
@en
Thalidomide metabolism by the CYP2C subfamily.
@nl
prefLabel
Thalidomide metabolism by the CYP2C subfamily.
@ast
Thalidomide metabolism by the CYP2C subfamily.
@en
Thalidomide metabolism by the CYP2C subfamily.
@nl
P2093
P1476
Thalidomide metabolism by the CYP2C subfamily
@en
P2093
Eiichi Fuse
William D Figg
Yukio Ando
P304
P407
P577
2002-06-01T00:00:00Z